Description  Claims  Drawing  Cited references 

WO9823645A   [0005] 
WO9957134A   [0012] 
WO2004024866A   [0012] 
WO2007117490A   [0012] 
WO2009058812A   [0012] 
WO2007108955A   [0012]  [0012] 
WO2004035792A   [0012] 
WO0194585A   [0013] 
US5655866A   [0070] 
WO01094585A   [0076] 
GB1012603A   [0118] 

Affinity-reversed-phase liquid chromatography assay to quantitate recombinant antibodies and antibody fragments in fermentation broth   [0117] 
A rapid method for determining dynamic binding capacity of resins for the purification of proteins   [0117] 
Studies on the expression of recombinant fuculose-1-phosphate aldolase in Escherichia coli   [0117] 
GE Healthcare data file 11-0025-76 AE   [0117] 
Antibody fragments. In Antibodies   [0117] 
Engineered antibody fragments and the rise of single domains   [0117] 
Production of antibodies and antibody fragments in Escherichia coli and a comparison of their functions, uses and modification   [0117] 
Therapeutic antibody production technologies: molecules, applications, expression and purification   [0117] 
Engineering of Escherichia coli to improve the purification of periplasmic Fab' fragments: changing the pl of the chromosomally encoded PhoS/PstS protein   [0117] 
Strategies for efficient production of heterologous proteins in Escherichia coli   [0117] 
Strategies for achieving high-level expression of genes in Escherichia coli   [0117] 
Evaluation of protein-A chromatography media   [0117] 
Downstream Processing of Monoclonal Antibody Fragments   [0117] 
Advances in Escherichia coli production of therapeutic proteins   [0117] 
Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems   [0117] 
Purification of proteins using displacement chromatography   [0117] 
Biopharmaceuticals: Approval Trends   [0117]